TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02576431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2757556 (Larotrectinib, Vitrakvi)
Description: Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2757556 (Larotrectinib, Vitrakvi)
Description: Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2757556 (Larotrectinib, Vitrakvi)
Description: Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2757556 (Larotrectinib, Vitrakvi)
Description: Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2757556 (Larotrectinib, Vitrakvi)
Description: Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2757556 (Larotrectinib, Vitrakvi)
Description: Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2757556 (Larotrectinib, Vitrakvi)
Description: Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2757556 (Larotrectinib, Vitrakvi)
Description: Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2757556 (Larotrectinib, Vitrakvi)
Description: Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2757556 (Larotrectinib, Vitrakvi)
Description: Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2757556 (Larotrectinib, Vitrakvi)
Description: Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.
Study: NCT01702480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2981710
Description: Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2981710
Description: Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2981710
Description: Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2981710
Description: Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
Study: NCT04658862

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Participants will receive intravenous Cetrelimab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAR-200
Description: Participants will receive intravesical TAR-200.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Participants will receive cisplatin intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants will receive gemcitabine intravenously.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiation therapy
Description: Participants will receive conventional radiation therapy for bladder (64 gy).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypo-fractioned radiation therapy
Description: Participants will receive hypo-fractioned radiation therapy for bladder (55 gy).
Study: NCT05253781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Description: Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will receive one tablet of the placebo which has same shape, size, thickness and colour as the LDA daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
Study: NCT02060591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Study: NCT01702480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2981710
Description: Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will be available as matching powder that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will be available as matching powder that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
Study: NCT02060591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Study: NCT01056588

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CO-Contingent
Description: In this 42 day condition, participants will receive monetary reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking (4ppm).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control condition
Description: In this condition, participants will receive monetary reinforcement for timely breath samples with no contingency for a specific breath CO level
Study: NCT00345319

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rabies vaccine
Description: Administration of PCECV according to ESSEN regimen

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rabies vaccine
Description: Administration of PCECV according to ESSEN regimen
Study: NCT00660335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1068 (synthetic human secretin)
Description: Single-dose, IV infusion
Study: NCT01352585

Intervention type: DRUG
Intervention: Anagrelide hydrochloride
Description: 0.5 mg hard capsules, dosing decisions will be made by the treating physician

Intervention type: DRUG
Intervention: Anagrelide hydrochloride
Description: 0.5 mg hard capsules, dosing decisions will be made by the treating physician
Study: NCT00412048

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fMRI to detect MCI patients who will convert to Alzheimer's disease
Description: There is a fMRI to be realized in the 3 arms. No drug is administered

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fMRI to detect MCI patients who will convert to Alzheimer's disease
Description: There is a fMRI to be realized in the 3 arms. No drug is administered

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fMRI to detect MCI patients who will convert to Alzheimer's disease
Description: There is a fMRI to be realized in the 3 arms. No drug is administered
Study: NCT03496974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab Monoclonal Antibody 200 mg
Description: 200 mg subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab Monoclonal Antibody 400 mg
Description: 400 mg subcutaneous injection
Study: NCT04407013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced supportive care based on standardized care pathway
Description: Enhanced supportive care based on standard care pathway is consisted of 1) symptom management (symptom assessment and according management) and 2) coping enhancement (nurse-led counseling). The enhanced supportive care will be provided 5 times, according to the standardized care pathway.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group with usual care
Description: Control group will receive usual care (symptom monitoring only)
Study: NCT03397680

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 13C Urea Breath Test
Description: After the H.pylori eradication treatment course completed, participants then was tested with 13C Urea Breath Test to confirm treatment effectiveness at least after ceasing PPI and antibiotics for 4 weeks.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 13C Urea Breath Test
Description: After the H.pylori eradication treatment course completed, participants then was tested with 13C Urea Breath Test to confirm treatment effectiveness at least after ceasing PPI and antibiotics for 4 weeks.
Study: NCT00649363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Orally Disintegrating Tablets 8 mg
Description: 8mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran ODT® Tablets 8 mg
Description: 8mg, single dose fasting
Study: NCT02691195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Nacl
Description: patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
Study: NCT04551599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: A single dose of danicopan (200 milligrams) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: A single dose of danicopan (200 milligrams) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: A single dose of danicopan (200 milligrams) will be administered orally.
Study: NCT04680325

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Juice daily consumption
Description: Single-service bottles of juice were provided for 15 days of daily consumption in each arm

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Juice daily consumption
Description: Single-service bottles of juice were provided for 15 days of daily consumption in each arm
Study: NCT00023647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synchrotope TA2M
Description: Cancer Vaccine, Immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synchrotope TA2M
Description: Cancer Vaccine, Immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synchrotope TA2M
Description: Cancer Vaccine, Immunotherapy
Study: NCT04372225

Intervention type: OTHER
Intervention: analysis of hypocalcemia
Description: analysis of postoperative calcium and PTH levels
Study: NCT04121884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy
Description: The ART protocol first uses the technique of imaginal exposure to elicit physiological reactions associated with patient recall from beginning to end (verbally or non-verbally) of a traumatic/distressing experience. As physiological reactions emerge, the participant is directed to focus their attention on the specific body-centric reactions while laterally performing smooth pursuit eye movements which are achieved by tracking the clinician's hand which oscillates from left-to-right at a short distance from the participant's eyes. Then the participant is directed to imagine a positive way in which they prefer to recall their experience(s), including emphasis on replacing negative images in the brain with positive images. This technique is based on the process of memory reconsolidation, which allows for adding of positive material to the recall of negative, highly emotional past experiences.
Study: NCT03630523

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influvac Tetra
Description: Tetravalent seasonal flu vaccination 2018/2019
Study: NCT00755222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500
Description: 2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series was separated by 6 weeks.
Study: NCT03375697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63733657
Description: Subjects will receive single (Part 1) or multiple (Part 2) ascending dose levels of JNJ-63733657 intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63733657
Description: Subjects will receive single (Part 1) or multiple (Part 2) ascending dose levels of JNJ-63733657 intravenously.
Study: NCT00755222

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series is separated by 6 weeks.
Study: NCT02384525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid management by the value of over hydration in Bioelectrical impedance
Description: In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid management by clinical-based ultrafiltration
Description: In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
Study: NCT04143334

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional survey

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional survey
Study: NCT04139980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: Each VR session is 30 minutes long. Participants are able to pause or discontinue at any time. Each participant will receive one VR sessions five times per week over the course of a two-week period.
Study: NCT02437474

Intervention type: BEHAVIORAL
Intervention: Omnivorous diet
Description: Adopting or continuing the selected diet for 6 months (omnivorous)

Intervention type: BEHAVIORAL
Intervention: Lacto-ovo-vegetarian diet
Description: Adopting or continuing the selected diet for 6 months (lacto-ovo-vegetarian)

Intervention type: BEHAVIORAL
Intervention: Vegan diet
Description: Adopting or continuing the selected diet for 6 months (vegan)
Study: NCT03396484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyldopa
Description: Tablet for oral dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral dosing
Study: NCT00978354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Continuous intravenous infusion of furosemide titrated to urine output

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Continuous intravenous infusion 0.9% normal saline placebo control
Study: NCT04617548

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: tDCS and CO-OP Group
Description: Transcranial direct current stimulation modulates the excitability of targeted brain regions, and is thought to facilitate or inhibit neuroplasticity. Participants will receive anodal tDCS (1.5 mA) to the dorsolateral prefrontal cortex (dlPFC) for 20 minutes at the beginning of each session. CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
Study: NCT03375697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching placebo intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching placebo intravenously.
Study: NCT04323332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine Prescription
Description: Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.
Study: NCT02356159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375 mg/m2 IV, day 1 for patients with CD20-positive disease
Study: NCT01011127

Intervention type: DRUG
Intervention: pravastatin, rosuvastatin

Intervention type: DRUG
Intervention: pravastatin, rosuvastatin
Study: NCT02356159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375 mg/m2 IV, day 1 for patients with CD20-positive disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning chemotherapy
Description: Fludarabine:30 mg/m2 per day IV infusion over 30 minutes, daily On days -6, -5, -4, and -3; Cyclophosphamide:1200 mg/m2 per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m2 per day IV infusion, Daily on days 6, -5,-4, and -3 Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3; Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3
Study: NCT03375840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-only PWL
Description: Control condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-only PWL
Description: Control condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-emot PWL
Description: Pictorial warning
Study: NCT03375840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-emot PWL
Description: Pictorial warning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-emot PWL
Description: Pictorial warning
Study: NCT02205216

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: anode over the motor and premotor cortex with cathodes placed over both mastoids. TDCS will be applied for 20 minutes at 2 mA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: anode and cathode placed 1 cm apart over the forehead and DC (1mA) applied for 1-2 min, short-circuited through the skin creating the same temporary tingling sensation without effects on the brain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Therapy
Description: All patients will undergo a rehabilitation therapy intervention (2x a week for 4 weeks = 8 intervention sessions) with simultaneous sham or active tDCS. The trained physiotherapist will follow a standardized program with checklist. Each of the 8 training session will last approximately 45min. The rehabilitative interventions include:~1. cognitive training: attentional strategies (mental counting, mental obstacle)~2. transfer training: everyday activities~3. motor training (walking) with sensory cueing (visual, acoustic, cane, ball) The rehabilitation therapy is divided into two sessions both including a 5 minutes warm-up and the learning of cueing and movement strategies based on different modalities (cognitive, visual, tactile and auditory).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation Therapy
Description: All patients will undergo a rehabilitation therapy intervention (2x a week for 4 weeks = 8 intervention sessions) with simultaneous sham or active tDCS. The trained physiotherapist will follow a standardized program with checklist. Each of the 8 training session will last approximately 45min. The rehabilitative interventions include:~1. cognitive training: attentional strategies (mental counting, mental obstacle)~2. transfer training: everyday activities~3. motor training (walking) with sensory cueing (visual, acoustic, cane, ball) The rehabilitation therapy is divided into two sessions both including a 5 minutes warm-up and the learning of cueing and movement strategies based on different modalities (cognitive, visual, tactile and auditory).
Study: NCT00548132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated foam dressing
Description: Patients in the treatment arm will have the Biopatch incorporated into their catheter care protocol. ICU nurses were instructed on the proper use of this novel dressing/sponge. Catheter dressing changes will only be done every 7 days unless there is visible blood, soiling underneath the dressing, or if the dressing comes off.
Study: NCT03375840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-emot PWL
Description: Pictorial warning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate posttest